Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: Pharmacokinetic, pharmacodynamic, and molecular interactions

Blood

Volumn 87, Issue 1, 1996, Pages 256-264

  Gandhi, Varsha ^a   Estey, Elihu ^a   Keating, Michael J ^a   Chucrallah, Antoine ^a   Plunkett, William ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLADRIBINE; CYTARABINE; VIDARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DNA SYNTHESIS; DRUG EFFICACY; HUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

EID: 0030042611     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.1.256.256     Document Type: Article

References (45)

1. Keating MJ, McCredie KB, Bodey GP, Smith TL, Gehan EA, Freireich EJ: Improved prospects for long-term survival in adults with acute myelogenous leukemia. JAMA 248:2481, 1982
2. Chu MY, Fischer GA: Comparative studies of leukemia cells sensitive and resistant to cytosine arabinoside. Biochem Pharmacol 14:333, 1965
3. Schrecker AW, Urshel MJ: Metabolism of 1-β-D-arabinofuranosykytosine in leukemia L1210: studies with intact cells. Cancer Res 28:793, 1968
4. Plunkett W, Hug V, Keating MJ, Chubb S: Quantitation of 1-β-D-arabinofuranosylcytosine 5′-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-β-D-arabinofuranosylcytosine therapy. Cancer Res 40:588, 1980
5. Plunkett W, Iacoboni S, Estey E, Danhauser L, Liliemark JO, Keating MJ: Pharmacologically directed ara-C therapy for refractory leukemia. Semin Oncol 12:20, 1985 (suppl 3)
6. Keating MJ, Estey EH, Plunkett W, Iacoboni S, Walters H, Kantarjian H, Andersson B, Beran M, McCredie KB, Freireich F: Evolution of clinical studies with high-dose cytosine arabinoside at the M.D. Anderson Hospital. Semin Oncol 12:98, 1985 (suppl 3)
7. Iacoboni SJ, Plunkett W, Kantarjian HM, Estey E, Keating MJ, McCredie KB, Freireich EJ: High-dose cytosine arabinoside: Treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis. J Clin Oncol 4:1079, 1986
8. Kantarjian HM, Estey EH, Plunkett W, Keating MJ, Walters RS, Iacoboni S, McCredie KB, Freireich EJ: Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia. Am J Med 81:387, 1986
9. Estey E, Plunkett W, Dixon DO, Keating M, McCredie K, Freireich EJ: Variables predicting response to high dose cytosine arabinoside therapy with refractory acute leukemia. Leukemia 1:580, 1987
10. Momparler RL, Fischer GA: Mammalian deoxynucleoside kmase. I. Deoxycytidine kinase: Purification, properties and kinetic studies with cytosine arabinoside. J Biol Chem 243:4298, 1968
11. Kessel D, Hall TC, Wodinsky I: Transport and phosphorylation as factors in the antitumor action of cytosine arabinoside. Science 156:1240, 1967
12. Gandhi V, Plunkett W: Modulation of arabinosyl nucleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res 48:329, 1988
13. Gandhi V, Nowak B, Keating MJ, Plunkett W: Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: Implications for combination therapy. Blood 74:2070, 1989
14. Gandhi V, Kemena A, Keating MJ, Plunkett W: Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. Cancer Res 52:897, 1992
15. Gandhi V, Robertson LE, Keating MJ, Plunkett W: Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: Clinical efficacy and modulation of arabinosylcytosine pharmacology. Cancer Chemother Pharmacol 34:30, 1994
16. Gandhi V, Estey E, Keating MJ, Plunkett W: Fludarabine potentiates metabolism of arabinosylcytosine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 11:116, 1993
17. Parker WB, Shaddix SC, Chang C-H, White EC, Rose LM, Brockman RW, Shortnacy AT, Montgomery JA, Secrist III JA, Bennett Jr LL: Effects of 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5′-triphosphate. Cancer Res 51:2386, 1991
18. Santana VM, Hurwitz CA, Blakley RL, Crom WR, Luo X, Roberts WM, Ribeiro R, Mahmoud H, Krance RA: Complete hematologic remissions induced by 2-chlorodeoxyadenosine in children with newly diagnosed acute myeloid leukemia. Blood 84:1237, 1994
19. Vahdat L, Wong ET, Wile MJ, Rosenblum M, Foley KM, Warrell RP Jr: Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia. Blood, 84:3429, 1994
20. Gandhi V, Estey E, Keating MJ, Plunkett W: Biochemical modulation of arabinosylcytosine for therapy of leukemias. Leuk Lymphoma 10:109, 1993 (suppl)
21. Kornblau S, Andreeff M, Beran M, Escudier S, Kantarjian H, Koller C, O'Brien S, Robertson LE, Estey E: 2-CdA ± ara-C is ineffective therapy for relapsed or refractory AML in adults. Proc Am Soc Clin Oncol 14:336, 1995
22. Gandhi V, Danhauser L, Plunkett W: Separation of 1-β-D-arabinofuranosylcytosine 5′-triphosphate and 9-β-D-arabinofuranosyl-2-fluoroadenine 5′-triphosphate in human leukemic cells by high performance liquid chromatography. J Chromatogr 413:293, 1987
23. Sherman PA, Fyfe FA: Enzymatic assay for deoxynucleoside triphosphates using synthetic oligonucleotides as template primers. Anal Biochem 180:222, 1989
24. Huang P, Farquhar D, Plunkett W: Selective action of 3′-azido-3′-deoxythymidine 5′-triphosphate on viral reverse transcriptases and human DNA polymerases. J Biol Chem 265:11914, 1990
25. Goodman MF, Creighton S, Bloom LB, Petruska J: Biochemical basis of DNA replication fidelity. Crit Rev Biochem Mol Biol 28:83, 1993
26. Chou J, Chou T: Dose-Effect Analysis With Microcomputers. Amsterdam, The Netherlands, Elsevier Science, 1985, p 5
27. Parker WB, Bapat AK, Shen J-X, Townsend AJ, Cheng Y-C. Interaction of 2-halogenated dATP analogs (F, Cl, and Br) with human DNA polymerases, DNA primase, and ribonucleotide reductase. Mol Pharmacol 34:485, 1988
28. Plunkett W, Liliemark JO, Adams TM, Nowak B, Estey E, Kantarjian H, Keating MJ: Saturation of 1-β-D-arabinosylcytosine 5′-triphosphate accumulation in leukemia cells during high-dose 1-β-D-arabinosylcytosine therapy. Cancer Res 47:3005, 1987
29. Plunkett W, Liliemark JO, Estey E, Keating MJ: Saturation of ara-CTP accumulation during high-dose ara-C therapy: Pharmacologic rationale for intermediate-dose ara-C. Semin Oncol 14:159, 1987 (suppl 1)
30. Hiddemann, W: Cytosine arabinoside in the treatment of acute myeloid leukemia: The role and place of high-dose regimens. Ann Hematol 62:119, 1991
31. Estey EH, Plunkett W, Kantarjian H, Rios MB, Keating MJ: Treatment of relapsed or refractory AML with intermediate-dose arabinosylcytosine (ara-C): Confirmation of the importance of ara-C triphosphate formation in mediating response to ara-C. Leukemia Lymphoma 10:115, 1993 (suppl)
32. Shewach DS, Reynolds KK, Hertel L: Nucleotide specificity of human deoxycytidine kinase. Mol Pharmacol 42:518, 1992
33. Gandhi V, Kemena A, Keating MJ, Plunkett W: Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy. Leuk Lymphoma 10:49, 1993
34. Liliemark J, Juliusson G: On the pharmacokinetics of 2-chlorodeoxyadenosine in humans. Cancer Res 51:5570, 1991
35. Liliemark J, Juliusson G: Cellular pharmacokinetics of 2-chloro-2′-deoxyadenosine nucleotides: Comparison of intermittent and continuous intravenous infusion and subcutaneous and oral administration in leukemia patients. Clin Cancer Res 1:385, 1995
36. Julliusson G, Liliemark J: High complete remission rate from 2-chloro-2′-deoxyadenosine (CdA) in previously treated patients with B-cell chronic lymphocytic leukemia: Response predicted by rapid decrease of blood lymphocyte count. J Clin Oncol 11:679, 1993
37. Piro LD, Carrera CJ, Beutler E, Carson DA: 2-Chlorodeoxyadenosine, an effective new agent for the treatment of chronic lymphocytic leukemia. Blood 72:1069, 1988
38. Piro LD, Carrera CJ, Carson DA Beutler E: Lasting remission in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 322:1117, 1990
39. Santana VM, Mirro J Jr, Kearns C, Schell MJ, Crom W. Blakley RL: 2-chlorodeoxyadenosine produces a high rate of complete remission in relapsed acute myeloid leukemia. J Clin Oncol 10:364, 1992
40. Eriksson S, Kierdaszuk B, Munch-Petersen B, Oberg B, Johansson NG: Comparison of the substrate specificities of human thymidine kinase 1 and 2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogs. Biochem Biophys Res Commun 176:586, 1991
41. Wang L, Karlsson A, Arner ESJ, Eriksson S: Substrate specificity of mitochondrial 2′-deoxyguanosine kinase: Efficient phosphorylation of 2-chlorodeoxyadenosine. J Biol Chem 268:22847, 1993
42. Reichard P: Interactions between deoxyribonucleotide and DNA synthesis. Annu Rev Biochem 57:349, 1988
43. Hentosh P, Koob R, Blakley RL: Incorporation of 2-halogeno-2′-deoxyadenosine 5′-triphosphates into DNA during replication by human polymerases α and β. J Biol Chem 265:4033, 1990
44. Chunduru SK, Appleman JR, Blakley RL: Activity of human DNA polymerase α and β with 2-chloro-2′-deoxyadenosine 5′-triphosphate as a substrate and quantitative effects of incorporation on chain extension. Arch Biochem Biophys 302:19, 1993
45. Hentosh P, Grippo P: Template 2-chloro-2′-deoxyadenosine monophosphate inhibits in vitro DNA synthesis. Mol Pharmacol 45:955, 1994